Dynavax Technologies Corporation (DVAX) : 4 analysts are covering Dynavax Technologies Corporation (DVAX) and their average rating on the stock is 2, which is read as a Buy. 2 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 4, which recommends a Sell affirms that they expect a large upside in the stock from the current levels. A total of 2 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Dynavax Technologies Corporation (DVAX) : The highest level Dynavax Technologies Corporation (DVAX) is projected to reach is $45 for the short term and the lowest estimate is at $17. The consolidated price target from 4 rating analysts who initiate coverage on the stock is $32.25 and the possibility the share price can swing is $14.86.
For the current week, the company shares have a recommendation consensus of Buy. Dynavax Technologies Corporation (NASDAQ:DVAX): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $15.82 and $15.75 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $16.22. The buying momentum continued till the end and the stock did not give up its gains. It closed at $16.06, notching a gain of 2.16% for the day. The total traded volume was 1,172,076 . The stock had closed at $15.72 on the previous day.
In a related news, Janssen Robert, Officer (Vice President) of DYNAVAX TECHNOLOGIES CORP, executed a transaction worth $19,863 on June 28, 2016. A total of 1,452 shares were purchased at an average price of $13.68. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are organized under three areas of focus: vaccine adjuvants, cancer immunotherapy, and autoimmune and inflammatory diseases. The Companys pipeline of product candidates includes HEPLISAV-B, an investigational adult hepatitis B vaccine, is in Phase III clinical trials; SD-101, a cancer immunotherapy candidate, is in Phase I/II clinical trials; AZD1419, a candidate drug for asthma, is in Phase II clinical trials planning; DV1179 is an inhibitor of TLR 7 and TLR 9 for autoimmune and inflammatory diseases, is in Phase I clinical trials. DV230-Nanoparticle is a second generation adjuvant. DV230-Nanoparticle is in preclinical stage.